ICON selected by BARDA to conduct anthrax vaccine clinical trial
ICON plc (NASDAQ: ICLR) has been selected by the US Biomedical Advanced Research and Development Authority (BARDA) to conduct a clinical trial for the AV7909 anthrax vaccine. Funded by BARDA, this trial aims to evaluate the immune response of healthy adults to the next-generation vaccine, with activities including project management and clinical operations. ICON has significant experience in vaccine studies, participating in over 160 trials in the past five years. The trial will start in early 2023, addressing the potential threat of anthrax exposure.
- Selected by BARDA to conduct AV7909 anthrax vaccine clinical trial.
- Funding provided by BARDA, affirming confidence in ICON's capabilities.
- Over 160 vaccine studies conducted in the past five years, showcasing expertise.
- None.
BARDA is providing funding to the Government and
ICON has extensive experience in supporting vaccine clinical trials. It has participated in over 160 vaccine studies in the past five years. ICON’s vaccine clinical research professionals are therapeutically aligned with a leadership team that brings more than 200 years of combined experience in vaccine clinical development for commercial businesses, government, NGOs and multinational health organisations.
This clinical study will inform operational logistics and use of AV7909 should an anthrax emergency occur. The clinical studies will not expose participants to anthrax. The trial will enrol healthy adults aged 18 and older and will be conducted in
BARDA, part of the Administration for Strategic Preparedness and Response within the
Bacillus anthracis, the agent that causes anthrax, is a serious bioterrorism threat due to the delivery of aerosolised spores that can cause high-mortality disease through gastrointestinal, cutaneous, inhalational (pulmonary), or injection routes. Although clinical manifestations of the disease differ by route, inhalational anthrax is the most lethal. Inhalational anthrax infection usually develops within a week after exposure but can take up to two months. Without treatment, only about
Since 2015, BARDA has supported the late-stage development of AV7909, a next-generation anthrax vaccine which uses the
About
ICON is the world’s leading clinical research organisation, powered by healthcare intelligence. From molecule to medicine, we advance clinical research providing outsourced development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in
About
About BARDA’s Medical Countermeasures Clinical Studies Network (CSN)
The CSN provides BARDA partners and medical countermeasure developers with essential tools and services to develop vaccines, therapeutics, diagnostics, and medical devices. The CSN provides comprehensive (Phases 1-4) clinical study services to help evaluate the safety, dosage, pharmacokinetics/pharmacodynamics, immunogenicity, and efficacy of medical countermeasure candidates, provide long-term storage services for clinical and nonclinical biological specimens and investigational products for future assays, and provide a statistical and data coordinating centre for harmonisation across BARDA projects. ICON plc’s work with BARDA is supported with federal funds under contract number 75A50120D00017.
ICON/ICLR-G
View source version on businesswire.com: https://www.businesswire.com/news/home/20221006005215/en/
Media:
Corporate Communications,
+353 87 4066091
claire.quinn@iconplc.com
Weber Shandwick (PR adviser)
lhenry@webershandwick.com
+447785 458203
Source:
FAQ
What is the purpose of ICON's clinical trial for the AV7909 anthrax vaccine?
When is the AV7909 clinical trial set to begin?
Who is funding ICON's anthrax vaccine clinical trial?
What kind of expertise does ICON have in vaccine studies?